Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35704054/
Therefore, due to the survival benefit after 3 years, current practice is changing. New palliative SOC is radiotherapy of the primary tumor in synchronously metastasized prostate cancer with low metastatic...
Conclusion: Therefore, due to the survival benefit after 3 years, current practice is changing. New palliative SOC is radiotherapy of the primary tumor in synchronously metastasized prostate cancer with low metastatic burden (defined as ≤ 4 bone metastases, with or without distant nodes) or in case of distant nodes only detected by...
Comprehensive review of hydrogel spacers prior to radiation therapy for prostate cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35689413/
Hydrogel spacers provide a low morbidity method potentially reducing rectal toxicity following radiation therapy in men with prostate cancer. Data outlining sexual function and oncologic outcomes are limited to date....
Conclusions: Hydrogel spacers provide a low morbidity method potentially reducing rectal toxicity following radiation therapy in men with prostate cancer. Data outlining sexual function and oncologic outcomes are limited to date. No doubt future studies, currently being conducted, may provide further clarification of the role of hydrogel spacers...
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35675470/
doi: 10.1002/pros.24396. Online ahead of print. 1 Department of Urology, University Hospital, Eberhard Karls University of Tübingen, Tübingen, Germany. 2 Department of Medicine, The University of Chicago, Chicago, Illinois, USA....
Conclusion: Enzalutamide plus ADT provides clinical benefits in defined patient subgroups versus ADT alone, while maintaining lack of pain and high HRQoL, with delayed deterioration in several HRQoL measures.
Cyclocreatine suppresses creatine metabolism and impairs prostate cancer progression - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35675421/
Prostate cancer is the second most common cause of cancer mortality in men worldwide. Applying a novel genetically engineered mouse model (GEMM) of aggressive prostate cancer driven by deficiency of...
Conclusion: Collectively, these results identify a metabolic vulnerability in prostate cancer and demonstrate a rational therapeutic strategy to exploit this vulnerability to impede tumour progression.
Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35652585/
Retrospective analysis of over 50,000 patients did not demonstrate an association between WPRT and an increased probability of SM compared to PORT. Given the findings of POP-RT, the use of...
Conclusions: Retrospective analysis of over 50,000 patients did not demonstrate an association between WPRT and an increased probability of SM compared to PORT. Given the findings of POP-RT, the use of WPRT may become widespread for certain subsets of men. Thus, our findings could help guide how we counsel patients deciding between WPRT and...